HGSI asks for FDA approval of anthrax drug ABthrax
Associated Press, 05.21.09, 08:00 AM EDT
Human Genome Sciences Inc. [link to board of directors] said Thursday it asked the Food and Drug Administration to approve ABthrax, a drug it is developing to treat inhaled anthrax. Human Genome Sciences submitted a Biologics License Application for ABthrax, or raxibacumab. The company is developing the drug for emergency use, such as a bioterrorist attack. Human Genome Sciences delivered 20,000 doses of the drug to the U.S. Strategic National Stockpile in the first quarter.
Saturday, May 30, 2009
Human Genome Sciences Inc. Seeks FDA Approval of Anthrax Drug ABthrax
Posted by Alex Constantine at 10:57 AM
Subscribe to: Post Comments (Atom)
Post a Comment